These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20883818)

  • 1. B-RAF: A contributor to the melanoma phenotype.
    Heath EM; Kaufman KL; Christopherson RI
    Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of B-RAF in melanoma.
    Gray-Schopfer VC; da Rocha Dias S; Marais R
    Cancer Metastasis Rev; 2005 Jan; 24(1):165-83. PubMed ID: 15785879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-RAF is a therapeutic target in melanoma.
    Karasarides M; Chiloeches A; Hayward R; Niculescu-Duvaz D; Scanlon I; Friedlos F; Ogilvie L; Hedley D; Martin J; Marshall CJ; Springer CJ; Marais R
    Oncogene; 2004 Aug; 23(37):6292-8. PubMed ID: 15208680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
    Wellbrock C; Marais R
    J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
    Christensen C; Guldberg P
    Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
    Cui Y; Borysova MK; Johnson JO; Guadagno TM
    Cancer Res; 2010 Jan; 70(2):675-84. PubMed ID: 20068179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
    Becker TM; Boyd SC; Mijatov B; Gowrishankar K; Snoyman S; Pupo GM; Scolyer RA; Mann GJ; Kefford RF; Zhang XD; Rizos H
    Oncogene; 2014 Feb; 33(9):1158-66. PubMed ID: 23455323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
    Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
    Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.